Detalhe da pesquisa
1.
The Prader-Willi Syndrome Anxiousness and Distress Behaviors Questionnaire: Development and Psychometric Validation.
Value Health
; 26(2): 243-250, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36202701
2.
Comparison of anchor-based methods for estimating thresholds of meaningful within-patient change using simulated PROMIS PF 20a data under various joint distribution characteristic conditions.
Qual Life Res
; 32(5): 1277-1293, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36371770
3.
Development and Validation Clinician and Patient Reported Photonumeric Scales to Assess Buttocks Cellulite Severity.
Dermatol Surg
; 46(12): 1628-1635, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33009069
4.
Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary.
Headache
; 57(9): 1385-1398, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28857154
5.
Planning in middle childhood: early predictors and later outcomes.
Child Dev
; 85(4): 1446-60, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24476334
6.
Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data.
Adv Ther
; 2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38775925
7.
Development and evaluation of the Acromegaly Symptom Diary.
J Patient Rep Outcomes
; 7(1): 15, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36792844
8.
Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores.
J Patient Rep Outcomes
; 7(1): 51, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37261682
9.
Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata.
Dermatol Ther (Heidelb)
; 12(1): 149-166, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34846634
10.
Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17ß-estradiol/progesterone.
Menopause
; 26(6): 637-642, 2019 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30601452
11.
Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI).
J Med Econ
; 22(9): 936-944, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31161828
12.
Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration.
Orphanet J Rare Dis
; 14(1): 174, 2019 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31300018
13.
A Scale to Assess Activities of Daily Living in Pantothenate Kinase-Associated Neurodegeneration.
Mov Disord Clin Pract
; 6(2): 139-149, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30838313
14.
Variation in expression of Biomphalaria glabrata SOD1: a potential controlling factor in susceptibility/resistance to Schistosoma mansoni.
Dev Comp Immunol
; 31(9): 874-8, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17292470
15.
Correction to: Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata.
Dermatol Ther (Heidelb)
; 12(5): 1287, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35399115
16.
Biomphalaria glabrata cytosolic copper/zinc superoxide dismutase (SOD1) gene: association of SOD1 alleles with resistance/susceptibility to Schistosoma mansoni.
Mol Biochem Parasitol
; 147(2): 207-10, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16564582
17.
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Mult Scler Relat Disord
; 6: 66-72, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27063626
18.
Respiratory burst of Biomphalaria glabrata hemocytes: Schistosoma mansoni-resistant snails produce more extracellular H2O2 than susceptible snails.
J Parasitol
; 91(2): 275-9, 2005 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15986600
19.
Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF.
Patient
; 8(4): 359-71, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26045359
20.
Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
Patient
; 8(5): 445-54, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26286337